Bausch Health Announces Early Exchange Offer Results for Exchange Offers
ACCESS Newswire (Mon, 8-Dec 7:23 PM ET)
Market Chameleon (Mon, 1-Dec 6:06 AM ET)
Market Chameleon (Mon, 1-Dec 3:41 AM ET)
ACCESS Newswire (Mon, 1-Dec 7:00 AM ET)
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
ACCESS Newswire (Mon, 24-Nov 7:05 AM ET)
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
ACCESS Newswire (Tue, 18-Nov 7:00 AM ET)
ACCESS Newswire (Wed, 5-Nov 8:00 AM ET)
Market Chameleon (Thu, 30-Oct 7:30 AM ET)
Bausch Health Announces Third Quarter 2025 Results
ACCESS Newswire (Wed, 29-Oct 4:05 PM ET)
Bausch Health Announces Results of Special Meeting of Shareholders
ACCESS Newswire (Thu, 9-Oct 7:00 AM ET)
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Bausch Health Companies trades on the NYSE stock market under the symbol BHC.
As of December 22, 2025, BHC stock price climbed to $7.00 with 1,514,082 million shares trading.
BHC has a beta of 0.94, meaning it tends to be less sensitive to market movements. BHC has a correlation of 0.05 to the broad based SPY ETF.
BHC has a market cap of $2.59 billion. This is considered a Mid Cap stock.
Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.16 earnings per share. This beat revenue expectation by $66 million and exceeded earnings estimates by $.10.
In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.
The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, PPH, DFIC, DISV, DFAX.
BHC has underperformed the market in the last year with a return of -5.3%, while SPY returned +18.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BHC shares. However, BHC has outperformed the market in the last 3 month and 2 week periods, returning +4.0% and +1.0%, while SPY returned +3.5% and +0.2%, respectively. This indicates BHC has been having a stronger performance recently.
BHC support price is $6.67 and resistance is $7.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.